Royce & Associates LP Increases Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Royce & Associates LP raised its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 17.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 341,000 shares of the company's stock after buying an additional 49,500 shares during the period. Royce & Associates LP owned approximately 0.16% of Hims & Hers Health worth $6,281,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Nisa Investment Advisors LLC grew its position in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock valued at $37,000 after acquiring an additional 1,603 shares in the last quarter. Quest Partners LLC lifted its holdings in Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company's stock worth $72,000 after purchasing an additional 3,507 shares during the last quarter. CWM LLC grew its position in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company's stock worth $110,000 after buying an additional 1,054 shares in the last quarter. Van ECK Associates Corp bought a new stake in shares of Hims & Hers Health in the 2nd quarter worth about $111,000. Finally, Amalgamated Bank increased its stake in shares of Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company's stock valued at $133,000 after buying an additional 2,354 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Stock Performance

Shares of HIMS stock traded up $1.67 during mid-day trading on Monday, reaching $20.99. 23,537,090 shares of the company's stock traded hands, compared to its average volume of 9,322,468. Hims & Hers Health, Inc. has a 12 month low of $7.50 and a 12 month high of $30.44. The firm has a 50 day moving average price of $19.76 and a two-hundred day moving average price of $18.92. The firm has a market capitalization of $4.51 billion, a PE ratio of 47.50 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to analysts' expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business's quarterly revenue was up 77.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.04) earnings per share. As a group, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on HIMS shares. Deutsche Bank Aktiengesellschaft upped their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research note on Wednesday, November 6th. Bank of America cut Hims & Hers Health from a "buy" rating to an "underperform" rating and dropped their price objective for the stock from $32.00 to $18.00 in a report on Thursday. Imperial Capital lowered shares of Hims & Hers Health from an "outperform" rating to an "in-line" rating in a report on Friday, August 9th. Piper Sandler reissued a "neutral" rating and set a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Finally, TD Cowen lifted their price target on shares of Hims & Hers Health from $25.00 to $28.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $20.71.

Insider Buying and Selling at Hims & Hers Health

In related news, Director Christiane Pendarvis sold 7,000 shares of the business's stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total transaction of $106,050.00. Following the transaction, the director now directly owns 23,917 shares in the company, valued at $362,342.55. The trade was a 22.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Andrew Dudum sold 188,888 shares of the company's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total value of $2,750,209.28. Following the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $487,789.12. This represents a 84.94 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 996,961 shares of company stock valued at $20,256,416. 17.71% of the stock is owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.